Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
申请人:Pierau Sabine
公开号:US20060046978A1
公开(公告)日:2006-03-02
This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and/or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof are useful for the treatment as well as the prevention of type 2 diabetes mellitus.
The invention is directed to compounds having the formula:
wherein: Ar, r, Y, Z, Q, W, X, and R
5-7
are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT
1
receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
The invention is directed to compounds having the formula:
wherein: Ar, r, R
2-3
, X, and R
5-7
are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT
1
receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.